Most Recent Articles
NICE social media
Payer acceptability of surrogate endpoints for adjuvant oncology therapies
The emergence of therapeutic radiopharmaceuticals
Swiping right on medical technology
R NICE lagging behind the world?
You reap what you sow
Is national HTA an optimal model for medical devices?
The impact of pCODR coming under the remit of CADTH
The OMAR era
Will CAR-T Cell Therapies change how drugs are priced and reimbursed?
Winning beyond the regulator
Innovative pricing and reimbursement schemes in the US
NICE end of life survival criterion
EAMs vs ATU
Putting the CAR-T before the horse
Is NICE cost-effective?
Health Technology Assessment in Bulgaria
The Biosimilar race in US and Europe
Variable Biosimilar coverage across US commercial plans